What are Stem Cells?
A mesenchymal stem cell is a primitive cell with the ability to:
What are Stem Cells?
A mesenchymal stem cell is a primitive cell with the ability to:
  • Self-Replicate
  • Differentiate into
    multiple tissues
  • Bone
  • Cartilage
  • Muscle
  • Fat
  • Fight Apoptosis
    (Cell Death)
  • Reduce Inflammation

2014- Comparative Outcomes of Open-Wedge High Tibial Osteotomy With Platelet-Rich Plasma Alone or in Combination With Mesenchymal Stem Cell Treatment: A Prospective Study. – The Journal of Arthroscopic and Related Surgery

Purpose: This study compared the clinical results and second-look arthroscopic findings of patients undergoing openwedge high tibial osteotomy (HTO) for varus deformity, with or without mesenchymal stem cell (MSC) therapy.

Methods: This prospective, comparative observational study was designed to evaluate the effectiveness of MSC therapy. The patients were divided into 2 groups: HTO with platelet-rich plasma (PRP) injection only (n ¼ 23) or HTO in conjunction with MSC therapy and PRP injection (n ¼ 21). Prospective evaluations of both groups were performed using the Lysholm score, Knee Injury and Osteoarthritis Outcome Score (KOOS), and a visual analog scale (VAS) score for pain. Second-look arthroscopy was carried out in all patients at the time of metal removal.

Results: The patients in the MSCPRP group showed significantly greater improvements in the KOOS subscales for pain (PRP only, 74.0  5.7; MSC-PRP, 81.2  6.9; P < .001) and symptoms (PRP only, 75.4  8.5; MSC-PRP, 82.8  7.2; P ¼ .006) relative to the PRP-only group. Although the mean Lysholm score was similarly improved in both groups (PRP only, 80.6  13.5; MSC-PRP, 84.7  16.2; P ¼ .357), the MSC-PRP group showed a significantly greater improvement in the VAS pain score (PRP only, 16.2  4.6; MSC-PRP, 10.2  5.7; P < .001). There were no differences in the preoperative (PRP only, varus 2.8  1.7; MSC-PRP, varus 3.4  3.0; P ¼ .719) and postoperative (PRP only, valgus 9.8  2.4; MSC-PRP, valgus 8.7  2.3; P ¼ .678) femorotibial angles or weight-bearing lines between the groups. Arthroscopic evaluation, at plate removal, showed that partial or even fibrocartilage coverage was achieved in 50% of the MSC-PRP group patients but in only 10% of the patients in the PRP-only group (P < .001).

Conclusions: MSC therapy, in conjunction with HTO, mildly improved cartilage healing and showed good clinical results in some KOOS subscores and the VAS pain score compared with PRP only.

Level of Evidence: Level II, prospective comparative study.

Click here to download the complete publication

  • American Academy of Orthopaedic Surgeons
  •  American Orthopaedic Society for Sports Medicine (AOSSM)
  • International Society for Hip Arthroscopy
  • Arthroscopy Association of North America – AANA
  • RYC Orthopaedics
  • Pro Medical New York
^ Back to Top